The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
C07D 217/20 - Radicaux aralkyle avec des atomes d'oxygène liés directement au noyau aromatique dudit radical aralkyle, p. ex. papavérine
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
C07D 489/00 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
C07D 489/10 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne condensés avec des carbocycles ou avec des systèmes carbocycliques avec un pont entre les positions 6 et 14
The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and elinafide, wherein less than 20% of the elinafide is released in vitro from the liposome within 40 hours. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid; and elinafide, wherein the administration of the liposomal composition has a reduced occurrence of side effects, such as for example, muscle myopathy in the patient.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
3.
MITOMYCIN C PRODRUG LIPOSOME FORMULATIONS AND USES THEREOF
The present invention provides MMC prodrug compounds and liposomal MMC prodrugs and compositions thereof for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid and a MMC prodrug. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid and a MMC prodrug or a pharmaceutically-acceptable salt thereof.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
The present invention provides improved stable liposomal formulations and method of preparation thereof. The liposomal formulations include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and a taxane, wherein the taxane is docetaxel or a derivative thereof. The liposomal formulations have improved stability and extended shelf-life. The present invention also provides pharmaceutical compositions comprising a liposomal formulation for the treatment of cancer.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
5.
(+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
C07D 217/20 - Radicaux aralkyle avec des atomes d'oxygène liés directement au noyau aromatique dudit radical aralkyle, p. ex. papavérine
C07D 489/00 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
C07D 489/10 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne condensés avec des carbocycles ou avec des systèmes carbocycliques avec un pont entre les positions 6 et 14
Processes for preparing 3-substituted phenylalkylamines comprising reacting a phenyl boronic compound with an α-β unsaturated carbonyl-containing compound via an asymmetric 1, 4-addition reaction, followed by reductive alkylation. The processes may be useful in the synthesis of tapentadol.
C07D 211/14 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 215/227 - Atomes d'oxygène liés en position 2 ou 4 un seul atome d'oxygène qui est lié en position 2
C07D 215/22 - Atomes d'oxygène liés en position 2 ou 4
7.
PREPARATION OF SUFENTANIL CITRATE AND SUFENTANIL BASE
Provided herein are processes for forming sufentanil citrate from sufentanil base. One process comprises forming sufentanil citrate in the presence of a polar non-aqueous solvent. Other processes comprise forming sufentanil citrate in the presence of water.
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
8.
SYSTEMS AND METHODS FOR HIGH HUMIDITY CURING WITHIN TABLET COATING SYSTEM
The disclosure encompasses systems and methods for performing high temperature and high humidity curing of tablets using air flow delivered from a recirculating air handler to a pan coater of a tablet coating device. The recirculating air handler may be integrated into a preexisting tablet coating device so that the air flow may be delivered by the preexisting air handler or by the recirculating air handler as desired.
B05C 7/02 - Appareillages spécialement agencés pour appliquer un liquide ou autre matériau fluide à l'intérieur d'une pièce creuse le liquide ou autre matériau fluide étant projeté
F24F 6/18 - Humidification de l'air par injection de vapeur dans l'air
B30B 11/34 - Presses spécialement adaptées à la fabrication d'objets à partir d'un matériau en grains ou à l'état plastique, p. ex. presses à briquettes ou presses à tablettes pour recouvrir des objets, p. ex. des tablettes
9.
MODIFIED DOCETAXEL LIPOSOME FORMULATIONS AND USES THEREOF
The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG- lipid, and a taxane, The PEG-lipid constitutes from about 2 to about 8 mol % of the lipids in the liposome. The taxane is docetaxel esterified at the 2'-O position with a heterocyciyl-(C2-5 alkanoic acid), The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient, in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid; and a taxane or a pharmaceutically acceptable salt thereof; wherein the taxane is docetaxel esterified at the 2'-O-position with a heterocyclyl-(C2-5 alkanoic acid); and wherein upon administration of the liposomal composition to the patient, the plasma concentration of docetaxel remain above an efficacy threshold of 0,2 μΜ for at least 5 hours.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
The invention provides methods for preparing substituted phenylalkanes. In particular, the processes comprise reacting a phenyl boronic compound with an α-β unsaturated carbonyl-containing compound via an asymmetric 1,4-addition reaction. The processes may be useful in the synthesis of tapentadol.
C07C 213/08 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné par des réactions n'impliquant pas la formation de groupes amino, de groupes hydroxy ou de groupes hydroxy éthérifiés ou estérifiés
C07C 217/62 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle, par l'intermédiaire de chaînes carbonées qui ne sont pas substituées de plus par des atomes d'oxygène liés par des liaisons simples reliés par l'intermédiaire de chaînes carbonées ayant au moins trois atomes de carbone entre les groupes amino et le cycle aromatique à six chaînons ou le système cyclique condensé contenant ce cycle
The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophilic gelling polymer, and an effervescent system.
The present disclosure provides compositions having different dissolution profiles. In particular, the compositions are formulated by adjusting the types and/or amounts of excipients and/or surfactants, and the compositions are prepared by spray drying processes.
C07D 455/03 - Composés hétérocycliques contenant des systèmes cycliques quinolizine, p. ex. alcaloïdes de l'émétine, protoberbérineDérivés alkylènedioxy des dibenzo [a, g] quinolizines, p. ex. berbérine contenant des systèmes cycliques quinolizine directement condensés avec au moins un carbocycle à six chaînons, p. ex. protoberbérineDérivés alkylènedioxy des dibenzo [a, g] quinolizines, p. ex. berbérine
C07D 217/20 - Radicaux aralkyle avec des atomes d'oxygène liés directement au noyau aromatique dudit radical aralkyle, p. ex. papavérine
C07D 221/18 - Systèmes cycliques d'au moins quatre cycles
14.
(+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat a variety of disorders.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
C07D 217/20 - Radicaux aralkyle avec des atomes d'oxygène liés directement au noyau aromatique dudit radical aralkyle, p. ex. papavérine
C07D 489/00 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
C07D 489/10 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne condensés avec des carbocycles ou avec des systèmes carbocycliques avec un pont entre les positions 6 et 14
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A leak testing system (210) for medicament sachets (200) is disclosed. The system (210) includes a base section (220) having a flat surface (226). A plurality of guide rods (230) extend from this flat surface (226) of the base section (220). A press section (240) incorporates a plurality of through-holes (242) that are used to movably mount the press section (240) on the noted guide rods (230). The press section (240) includes a flat surface (246) that is maintained in at least substantially parallel relation to the flat surface (226) of the base section (220). A medicament pouch (200) may be compressed between these flat surfaces (226, 246) of the base section (220) and the press section (240) by sliding the press section (240) along the guide rods (230) and in the direction of the base section (240). Multiple press plates can be added to adjust the force and weight to test for leaks.
The present invention provides processes for preparing normorphinans from N-substituted morphinans. In particular, the invention provides methods for removing the N-substituent from the N-substituted morphinan to from a normorphinan carbamate, and then removing the carbamate functionality from the normorphinan carbamate to form the normorphinan.
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
17.
PRODUCTION OF 6-HYDROXY MORPHINANS WITHOUT THE ISOLATION OF INTERMEDIATES
The present invention provides a process for preparing a saturated 6,14-dihydroxy morphinan. The process comprises contacting an unsaturated 6-O-hydrocarbyl morphinan with hydrogen peroxide and an organic acid to form an unsaturated 6-keto-14-hydroxy morphinan. The unsaturated 6-keto-14-hydroxy morphinan is contacted with a first reducing agent to form an unsaturated 6,14-dihydroxy morphinan, and the unsaturated 6,14-dihydroxy morphinan is contacted with a second reducing agent to form the saturated 6,14-dihydroxy morphinan.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
Described herein are one-pot methods for preparing N-alkyl morphinan-6-ols from morphinan-6-ones. In particular, the methods comprise contacting a morphinan-6-one with a boron-based reducing agent and either a carbonyl compound, an acylating agent, or an alkylating agent. Disclosed herein are one-pot methods wherein the NH group is treated with a carbonyl compound, such as an aldehyde or ketone, and a reducing agent, and wherein the 6-keto group is reduced to a 6-hydroxy group; one-pot methods wherein the NH group is treated with an alkylating agent and a base, thereby generating an N-alkyl group, and wherein the 6-keto group is reduced to a 6-hydroxy group by the addition of a reducing agent; and methods wherein the NH group is acylated with an acylating agent and a base, thereby generating an N-acyl group, and wherein the 6-keto group is reduced to a 6-hydroxy group by the addition of a reducing agent.
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
The present invention provides substituted berbines, processes for the synthesis of substituted berbine compounds preferably through a Bischler-Napieralski cyclization followed by reduction, as well as intermediates used in the synthesis of substituted berbine compounds. The amide precursor for the Bischler-Napieralski reaction could be obtained treating the free amine with acid halides, formate sources or aldehydes. Also provided are methods for using the substituted berbines to inhibit cancer cell growth.
C07D 455/03 - Composés hétérocycliques contenant des systèmes cycliques quinolizine, p. ex. alcaloïdes de l'émétine, protoberbérineDérivés alkylènedioxy des dibenzo [a, g] quinolizines, p. ex. berbérine contenant des systèmes cycliques quinolizine directement condensés avec au moins un carbocycle à six chaînons, p. ex. protoberbérineDérivés alkylènedioxy des dibenzo [a, g] quinolizines, p. ex. berbérine
20.
PREPARATION OF RADIOIODINATED 3-FLUOROPROPYL-NOR-BETA-CIT
The invention generally provides processes for the preparation of radioiodinated 3-fluoropropyl-nor-β-CIT. In particular, the process uses an arylsilane intermediate, thus avoiding the use of hexamethylditin, and reducing the number of steps previously required for the preparation of radioiodinated 3-fluoropropyl-nor-β-CIT from anhydroecgonine methyl ester. The invention also relates to the alkylation of a nortropane to the corresponding N-(3-fluoropropyl) analogue using 3-fluoropropanal.
A piezo motor (150) may be tuned to a specific frequency range having a small deviation from an operational frequency range of a magnetic resonance imaging system component. This may be done by applying a pressure to the piezo motor (150), generating at least one signal via a control board (200) and where this signal is at a selected frequency within the specific frequency range applying the signals to the piezo motor (150), measuring a vibration frequency of the piezo motor (150), and varying the applied pressure to the piezo motor (150). The applied pressure may continue to be adjusted until the measured vibration frequency of the piezo motor (150) is at a resonant frequency for the piezo motor (150). After the piezo motor (150) is tuned in this manner, the piezo motor (150) may be incorporated into a magnetic resonance imaging system component.
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61B 19/00 - Instruments, outillage ou accessoires pour la chirurgie ou le diagnostic non couverts par l'un des groupes A61B 1/00-A61B 18/00, p.ex. pour stéréotaxie, opération aseptique, traitement de la luxation, protecteurs des bords des blessures(masques de protection du visage A41D 13/11; blouses de chirurgien ou vêtements pour malades A41D 13/12; dispositifs pour retirer, traiter ou transporter les liquides du corps A61M 1/00)
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
The present disclosure generally relates to a new process for generating germanium-68 from an irradiated target body. The process includes irradiation of the target body followed by various extraction techniques to generate the germanium-68.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
G21G 1/10 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs à l'extérieur des réacteurs nucléaires ou des accélérateurs de particules par bombardement avec des particules électriquement chargées
23.
SYSTEMS AND METHODS FOR ASSAYING AN ELUATE FOR TECHNETIUM AND MOLYBDENUM CONTENT
A system for assaying an eluate for Technetium-99m and Molybdenum-99 content includes an inner ionization chamber including a well configured to receive the eluate, an outer ionization chamber concentric with the inner ionization chamber, and attenuating material positioned between the inner and outer ionization chambers. A computing device is configured to determine a Technetium-99m content of the eluate based on a first current measured in the inner ionization chamber, and determine a Molybdenum-99 content of the eluate based on at least a second current measured in the outer ionization chamber.
A system for receiving a needle includes a valve that defines a fluid flow channel, and a housing having a first end, a second end, and a receiving portion. The system further includes a septum formed from a resilient material and mounted in the housing. The septum includes a head portion including a tapered opening, a sealing portion, and an expansion portion extending from the head portion opposite the tapered opening. The expansion portion includes a chamber having a closed end, at least one relief channel, and a plurality of apertures formed in the relief channel. The plurality of apertures facilitates fluid communication between the chamber and the receiving portion when the expansion portion is in an open position.
The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-65 mol % of a phosphatidylcholine lipid, 30-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and cisplatin. Cisplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the cisplatin weight is from about 65:1 to about 95:1. Methods for the preparation of liposomal cisplatin and the treatment of cancer are also disclosed.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-70 mol % of a phosphatidylcholine lipid, 25-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and oxaliplatin. Oxaliplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the oxaliplatin weight is from about 20:1 to about 65:1. Methods for the preparation of liposomal oxaliplatin and the treatment of cancer are also disclosed.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and a taxane. The PEG-lipid constitutes from about 2 to about 8 mol % of the lipids in the liposome. The taxane is docetaxel esterified at the 2'-O position with a heterocyclyl-(C2-5alkanoic acid). Methods for preparation of liposomal taxanes and treatment of cancer with liposomal taxanes are also disclosed.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
28.
COMPOSITIONS COMPRISING AN OPIOID AND AN ADDITIONAL ACTIVE PHARMACEUTICAL INGREDIENT FOR RAPID ONSET AND EXTENDED DURATION OF ANALGESIA THAT MAY BE ADMINISTERED WITHOUT REGARD TO FOOD
The present disclosure provides pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state. The present disclosure further provides pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides reduced abuse potential.
The present invention provides compound conjugates of matrix metalloprotease inhibitors and linked metal chelators which are useful for imaging solid tumors and treating and diagnosing certain types of diseases such as cancer.
The present disclosure provides an immediate release, abuse deterrent pharmaceutical solid dosage form comprising at least one functional score. In particular, the immediate release, abuse deterrent solid dosage form comprises at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.
A61K 9/46 - Pilules, pastilles ou comprimés effervescents
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
EXTENDED RELEASE COMPOSITIONS COMPRISING HYDROCODONE AND ACETAMINOPHEN FOR RAPID ONSET AND PROLONGED ANALGESIA THAT MAY BE ADMINISTERED WITHOUT REGARD TO FOOD
The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.
The present disclosure relates generally to a pharmaceutical solution comprising hydromorphone or a pharmaceutically acceptable salt thereof that is substantially free of buffer and optionally one or more other additives. The pharmaceutically acceptable salt may be hydromorphone hydrochloride. Also disclosed are methods for the manufacture and use of the solution.
The present invention provides systems and methods for producing radiomedical-grade Tc-99m. In particular, the present invention provides systems and methods for producing Tc-99m by proton-irradiation of Mo-100 targets and subsequent separation of the resulting Tc-99m from the irradiated targets.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
G21G 1/10 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs à l'extérieur des réacteurs nucléaires ou des accélérateurs de particules par bombardement avec des particules électriquement chargées
34.
PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES
The present disclosure relates generally to a process for the synthesis of 1,4,7,10-tetraazacyclododecane ligands, chelates, and derivatives thereof. In particular, the present disclosure is directed to a process for the synthesis of 1,4,7,10-tetraaza-1,4,7,10-tetrakis(carboxymethyl)cyclododecane (DOTA) ligands, corresponding DOTA-metal chelates, and various derivatives thereof.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
A protective shroud (75) is provided for covering a radiation shield (20) that surrounds a nuclear pharmacy generator. The radiation shield includes components having seams (300) therebetween. The protective shroud includes a tubular body (306) configured to contain the radiation shield, a first opening (304) adapted for receiving the radiation shield, and a second opening (302) for allowing access into the radiation shield.
G21F 5/00 - Récipients blindés portatifs ou transportables
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
The present disclosure provides pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, optionally at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties. Also provided are methods for preparing the pharmaceutical compositions in which the components of the composition are humidified such that the deliquescent plasticizer deliquesces, thereby plasticizing the hydrophilic polymers.
An elution tool (150) for a radiopharmaceutical elution system includes an elution tool. The tool has a vial chamber sized and shaped for receiving an elution vial (17). An access opening is aligned with a septum of the elution vial when the elution vial is received in the vial chamber. An elution tool lid (158) is secured to the elution tool body by a hinged connection. The elution tool lid is rotatable at the hinged connection (186) and movable relative to the elution tool body between an occluded position and an exposed position. The tool also includes a latching mechanism (188) for selectively and releasably locking the lid in the occluded position.
Contrast administration data that relates to operation of a contrast media injector system (602) may be converted from at least one format (e.g., a CAN-compliant format) to at least one other format (e.g., an HL-7-compliant format) by an injection data management module (660) for use by a medical system (600). Data on contrast media prescribed for an imaging operation using an imaging system (690), contrast media data for use in this imaging operation, and data on contrast media actually administered/injected by a contrast media injector system (602) for this imaging operation may be stored in a data structure (780) on the injection data management module (660). Patient renal function data may be used to control the dispensing of contrast media from a contrast media/storage/dispensing unit (500), to control the operation of the contrast media injector system (602), or both, and may be stored in the data structure (780) as well.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
39.
IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS WITH ABUSE DETERRENT PROPERTIES
The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight water-soluble polymer, at least one polyglycol, at least one polysaccharide, at least one clay mineral, and, optionally, an effervescent system.
The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.
Multiple embodiments of contrast media injector systems (800, 800', 800c) are disclosed. A number of different devices are disclosed for providing user input to such a contrast media injector system (800, 800', 800c), including at least one tablet computer (700), a user-mountable user input device (760), a smartphone (762), and various combinations thereof.
The present invention provides processes for preparing nal-opiates without the isolation of intermediates. In general, the process provides for alkylation and reduction in the same pot to give the nal-opi- ate (I).
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
A holder (250) for a vial (252) containing a sterile liquid for use with a radiopharmaceutical elution system includes a holder body (254). The body has a top (260), an opposing bottom (262), an opening in the top and a vial chamber (264). The vial chamber extends from the opening in the top toward the bottom and is sized and shaped for receiving the vial therein. An access opening extends through the bottom to the vial chamber and is aligned with a septum of the elution vial when the sterile vial is received in the vial chamber. A cap (256) is removably secured to the top of the holder body (254) for selectively opening and closing the vial chamber (264). The holder body includes plastic and has a density less than the density of the cap.
G21F 1/00 - Blindage caractérisé par la composition du matériau
G21F 5/015 - Récipients blindés portatifs ou transportables pour le stockage de sources radioactives, p. ex. supports de sources pour unités d'irradiationRécipients pour radio-isotopes
45.
PROCESS FOR THE PRODUCTION OF SEVEN-MEMBERED LACTAM MORPHINANS
The present invention relates to improved processes for preparing lactam morphinans. The processes generally transform keto-morphinans to seven-membered lactam morphinans using a hydroxyamine sulfonic acid reagent and proceed in high yield and with good selectivity.
C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus dans les groupes , , ou dans lesquels le système condensé contient au moins quatre hétérocycles
The present invention relates to targeted delivery compositions comprising matrix metalloproteinase (MMP) inhibitors and methods of using the compositions for treating and diagnosing a disease state in a subject.
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A hand-actuated injector (10) includes a handle assembly (200) for providing discharge and aspiration strokes for a plunger (108). The handle assembly (200) includes first and second scissor-like handle members (204, 212) that provide a discharge stroke for the plunger (108) when manipulated in a first manner, and an aspiration stroke for the plunger (108) when manipulated in an opposite, second manner. The handle assembly (200) also includes a meshed-gear locking mechanism or hinge (248) that selectively prevents or at least limits relative movement between the first and second handle members (204, 212) in a manner that is associated with providing an aspiration stroke for the plunger (108).
A handle assembly (100) for a hand-actuated fluid delivery device (10) is disclosed. The handle assembly (100) includes a first handle member (110) that is mounted on a pivot (126) fixed to a second handle member (120). A locking spring (130) is mounted on this pivot (126). This locking spring (130), together with a corresponding actuator (140), cooperate to selectively provide resistance to movement of a plunger (30) in an aspiration direction in at least certain conditions. Disposing the actuator (140) in a locking position disposes the locking spring (130) in a locking configuration. Sliding friction or sliding friction forces between the locking spring (130) and the pivot (126), with the locking spring (130) being in its locking configuration, provides resistance to movement of the first handle member (110) relative to the second handle member (120) in a manner that would move the plunger (30) in an aspiration direction.
The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
Power injector control logic (110) that includes ramp-up logic (120) is disclosed. The ramp-up logic (120) controls an input signal to a motorized drive source of a power injector to advance the drive ram from a stationary state to an initial velocity that is associated with an initial flow rate(114) of an injection protocol (112) to be executed by the power injector.
The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject. Components of the targeted delivery compositions are put together through duplex formation between oligonucleotides.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
52.
OPTICAL AGENTS FOR IMAGING AND VISUALIZATION OF MATRIX METALLOPROTEINASE ENZYMES
The invention relates generally to optical agents for biomedical applications including imaging, visualization, phototherapy and diagnostic monitoring of cells and tissue expressing MMPs and/or tissues associated with the expression of MMPs. In some embodiments, for example, optical agents of the present invention selectively bind to, or otherwise preferentially associate with, a target tissue expressing one or more MMPs, and function to couple electromagnetic radiation into and/or out of the target tissue, for example via optical absorption, fluorescence, scattering and/or optoacoustic processes.
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/08 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles alicycliques
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
54.
REMOTE ASSEMBLY OF TARGETED NANOPARTICLES USING H-PHOSPHONATE-ENE/-YNE HYDROPHOSPHONYLATION REACTIONS
The present invention provides phosphonate compounds and methods of preparing the phosphonate compounds so as to allow, for example, increased capability to modify nanoparticles for targeted drug delivery applications.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicide; Pharmaceutical preparations for the treatment of pain, cough and upper respiratory symptoms, opioid addiction, insomnia, depression, and behavioral disorders; contrast media for use in medical imaging procedures; of radiopharmaceutical preparations for use in nuclear medicine; Pharmaceutical kits for the preparation of radiopharmaceutical preparations; syringes sold filled with saline solution; in Class 5.
57.
STEPWISE PROCESS FOR THE PRODUCTION OF ALKALOID SALTS
The present Invention provides to an improved process for preparing alkaloid salts. In particular, the process comprises a stepwise addition of an acid to an alkaloid chosen from hydrocodone, codeine, and dihydrocodeine to form a flowable mixture of the alkaloid salt
A powerhead (50) of a power injector is disclosed that includes a syringe housing (110) that contains a capacitive fluid detector (112). The capacitive fluid detector (112) may be operable to detect fluid within a syringe (116) installed on the syringe housing (110). The output of the capacitive fluid detector (112) may be used to estimate the volume of fluid within the syringe (116). The capacitive fluid detector (112) may include a plurality of discrete capacitors (118a-118h) arranged serially along a longitudinal axis (120) of the syringe (116). Each of the plurality of capacitors (118a-118h) may be operable to produce an electric field extending into the syringe (116). Each of the plurality of capacitors (118a-118h) may be formed on a printed circuit board (130).
An injection data management system (172) is disclosed. Injection-related data (182) is stored on the injection data management system (172) on a customer-by-customer (122) basis. A given customer (122) may communicate with the injection data management system (172) over the Internet (160) using an appropriate data communications device (124). Upon providing appropriate authenticating data (146) to the system (172), a customer (122) can access, view, and/or assess its own injection-related data (182) that is stored on the system (172) over the Internet (160).
G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
A process for producing Tc-99m comprises the steps of contacting a solution of purified Mo-99 with an adsorbent material comprising i) a tin oxide, or ii) a zirconium oxide and a titanium oxide, such that the Tc-99m resulting from the decay of Mo-99 may thereafter be eluted.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
61.
REDUCTIVE AMINATION OF 6-KETO MORPHINANS BY CATALYTIC HYDROGEN TRANSFER
The present invention provides compositions of 6-amino morphinan compounds and process for their synthesis. In particular, the processes provide for the reductive amination of 6-keto morphinans by catalytic transfer hydrogenation, to produce 6-amino morphinan compounds, which are epimerically and/or diastereomerically enriched.
Contrast administration data that relates to operation of a contrast media injector system (602) may be converted from at least one format (e.g., a CAN-compliant format) to at least one other format (e.g., an HL-7- compliant format) for use by a medical system (600). Data on contrast media prescribed for an imaging operation using an imaging system (690), data on contrast media dispensed from a contrast media storage/dispensing unit (500) for use in this imaging operation, and data on contrast media actually administered/injected by a contrast media injector system (602) for this imaging operation may be stored in a data structure (780). Patient renal function data may be used to control the dispensing of contrast media from the contrast media/storage/dispensing unit (500), to control the operation of the contrast media injector system (602), or both, and may be stored in the data structure (780) as well.
G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
63.
APPARATUS AND METHOD TO DETERMINE CONTRAST MEDIA INJECTION PARAMETERS TO CONTROL SIGNAL INTENSITY DURING MAGNETIC RESONANCE ANGIOGRAPHY
Injection systems and related methods including an injection device, an operator interface, and modules to determine operational parameters during an MRA imaging procedure. Such parameters may be used to optimize and/or maximize signal intensity during an MRA imaging procedure. The injection system may include a target in-bloodstream contrast agent concentration determination module that determines a target in-bloodstream contrast agent concentration at least partially based on contrast agent type and MRA imager parameters. The injection system may include a contrast agent injection rate determination module that determines a contrast agent injection rate at least partially based on the target in-bloodstream contrast agent concentration, an initial contrast agent concentration, and a cardiac output rate of a patient to be imaged. The injection system may include a diluent injection rate determination module that determines a diluent injection rate at least partially based on the contrast agent injection rate.
A process of treating hydrogen gas liberated from the acid or alkaline dissolution of a metal is provided. The process comprises a step of passing the liberated hydrogen gas through a reactor containing an oxidising agent for oxidation of the hydrogen gas into water, followed by a step of regenerating the oxidising agent. Also provided is an apparatus for carrying out the process, the apparatus comprising a reactor containing the oxidising agent, wherein the reactor is at least partially immersed in an alumina bath.
C01B 3/08 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés inorganiques comportant un hydrogène lié électropositivement, p. ex. de l'eau, des acides, des bases, de l'ammoniac, avec des agents réducteurs inorganiques avec des métaux
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Active chemical ingredients for use in the manufacture of pharmaceuticals for the relief of pain, opioid addiction, behavioral disorders, diabetes, and prostate cancer; excipients and chemical additives for use in the manufacture of pharmaceuticals and food; pharmaceutical preparations for the relief of pain and the treatment of opioid addiction, insomnia, depression, and behavioral disorders.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating pain, cough and upper respiratory symptoms, opioid addiction, behavioral disorders, diabetes, and prostate cancer; Excipients and chemical additives for use in the manufacture of pharmaceuticals and food; Chemicals for use in the manufacture of radiopharmaceuticals; in Class 1. Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicide; Pharmaceutical preparations for the treatment of pain, cough and upper respiratory symptoms, opioid addiction, insomnia, depression, and behavioral disorders; contrast media for use in medical imaging procedures; of radiopharmaceutical preparations for use in nuclear medicine; Pharmaceutical kits for the preparation of radiopharmaceutical preparations; syringes sold filled with saline solution; in Class 5. Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; orthopedic articles; suture materials; Power injectors for medical imaging procedures, parts and accessories therefore; Contrast media warmers; Medical generators for use in the production and transportation of nuclear medicine, parts and accessories therefore; Elution shields; Radioaerosol generators; Medical imaging apparatus and instruments in the field of urology, parts and accessories therefore; in Class 10.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating, pain, cough and upper respiratory symptoms, opioid addiction, behavioral disorders, diabetes, and prostate cancer; Excipients and chemical additives for use in the manufacture of pharmaceuticals and food; Chemicals for use in the manufacture of radiopharmaceuticals; in Class 1. Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicide; Pharmaceutical preparations for the treatment of pain, cough and upper respiratory symptoms, opioid addiction, insomnia, depression, and behavioral disorders; contrast media for use in medical imaging procedures; of radiopharmaceutical preparations for use in nuclear medicine; Pharmaceutical kits for the preparation of radiopharmaceutical preparations; syringes sold filled with saline solution; in Class 5. Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; orthopedic articles; suture materials; Power injectors for medical imaging procedures, parts and accessories therefore; Contrast media warmers; Medical generators for use in the production and transportation of nuclear medicine, parts and accessories therefore; Elution shields; Radioaerosol generators; Medical imaging apparatus and instruments in the field of urology, parts and accessories therefore; in Class 10.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating pain, cough and upper respiratory symptoms, opioid addiction, behavioral disorders, diabetes, and prostate cancer; Excipients and chemical additives for use in the manufacture of pharmaceuticals and food; Chemicals for use in the manufacture of radiopharmaceuticals; in Class 1. Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicide; Pharmaceutical preparations for the treatment of pain, cough and upper respiratory symptoms, opioid addiction, insomnia, depression, and behavioral disorders; contrast media for use in medical imaging procedures; of radiopharmaceutical preparations for use in nuclear medicine; Pharmaceutical kits for the preparation of radiopharmaceutical preparations; syringes sold filled with saline solution; in Class 5. Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; orthopedic articles; suture materials; Power injectors for medical imaging procedures, parts and accessories therefore; Contrast media warmers; Medical generators for use in the production and transportation of nuclear medicine, parts and accessories therefore; Elution shields; Radioaerosol generators; Medical imaging apparatus and instruments in the field of urology, parts and accessories therefore; in Class 10.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating pain, cough and upper respiratory symptoms, opioid addiction, behavioral disorders, diabetes, and prostate cancer; Excipients and chemical additives for use in the manufacture of pharmaceuticals and food; Chemicals for use in the manufacture of radiopharmaceuticals; in Class 1. Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicide; Pharmaceutical preparations for the treatment of pain, cough and upper respiratory symptoms, opioid addiction, insomnia, depression, and behavioral disorders; contrast media for use in medical imaging procedures; of radiopharmaceutical preparations for use in nuclear medicine; Pharmaceutical kits for the preparation of radiopharmaceutical preparations; syringes sold filled with saline solution; in Class 5. Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; orthopedic articles; suture materials; Power injectors for medical imaging procedures, parts and accessories therefore; Contrast media warmers; Medical generators for use in the production and transportation of nuclear medicine, parts and accessories therefore; Elution shields; Radioaerosol generators; Medical imaging apparatus and instruments in the field of urology, parts and accessories therefore; in Class 10.
A medical fluid injector system (450) is disclosed that may utilize one or more of flow rate determination logic (130), injection volume determination logic (132), display control logic (134), drive ram motion control logic (136), and pressure monitoring logic (138). The flow rate determination logic (130), injection volume determination logic (132), and display control logic (134) each may utilize a concentration input (172, 192, 202) to calculate flow rates, injection volumes, and generate multi-color graphics, respectively, for a simultaneous injection configuration. The drive ram motion control logic (136) may utilize both a target pressure and a monitored pressure to derive a velocity for advancing a drive ram. The pressure monitoring logic (138) may provide a monitored pressure value for the drive ram control logic (136), where this monitored pressure value may be derived from the input power being used to advance a drive ram and the drive ram velocity.
Various embodiments are disclosed that incorporate renal function check functionality in relation to contrast media injections. A contrast media injector system (430) may incorporate a data store (414) having a plurality of records (419), each of which includes data on contrast media type (416) and a corresponding threshold renal function (418). The contrast media injector system (430) and/or an imaging device (422) may incorporate a renal function assessment module (442). This module (442) may be configured with a protocol (480) that compares threshold renal function data with patient renal function data, and furthermore may be configured to only allow an injection to proceed if the patient renal function data complies with the relevant threshold renal function data. The threshold renal function data may be retrieved from a data storage device (516) incorporated by a syringe (504) installed on the contrast medical injector system (430).
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
73.
PROCESS FOR EXTRACTING CS-137 FROM AN ACIDIC SOLUTION
A process for extracting Cs-137 from i) an acidic solution obtained by dissolving an irradiated solid target comprising uranium, ii) an acidic solution comprising uranium which has previously been irradiated in a nuclear reactor, or iii) an acidic solution comprising uranium which has been used as reactor fuel in a homogeneous reactor, the acidic solution i), ii) or iii) having been treated to harvest Mo-99, wherein the process comprises contacting the treated acidic solution with an adsorbent comprising ammonium molybdophosphate (AMP). In an embodiment, the AMP is combined with an organic or inorganic polymeric support, for example AMP synthesised within hollow aluminosilicate microspheres (AMP-C).
G21G 1/08 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs à l'extérieur des réacteurs nucléaires ou des accélérateurs de particules par irradiation par des neutrons accompagnée de fission nucléaire
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
74.
APTAMER CONJUGATES FOR TARGETING OF THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS
The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject. In one aspect, the targeted delivery compositions of the present invention can include a targeted delivery compositon, comprising: (a) a nanocarrier including a therapeutic or diagnostic agent or a combination thereof; and (b) a conjugate having the formula: A- [(EG) (P)]n-T; wherein, A is an attachment component for attaching the conjugate to the nanocarrier; [(EG) (P)]n is a linking group, wherein the subscript n is an integer from 1 to about 40; and each EG is independently selected from a group consisting of triethylene glycol, tetraethylene glycol, pentaethylene glycol, hexaethylene glycol, heptaethylene glycol, and octaethylene glycol; P is independently selected from a group consisting of phosphate and thiophosphate; and, T is a targeting agent.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
75.
IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS
The present disclosure generally related to an improved process for the preparation of various piperidine derivatives. More particularly, the present disclosure related to an improved process for preparing sufentanil base (1) and related compounds, which advantageously utilizes more cost effective and/or less hazardous reagents, including a dispersion comprising between about 50% and about 70% by weight (based on the total weight of the dispersion) of an alkali metal hydride, such as sodium hydride, as well as eliminates the need for expensive and/or time consuming purification techniques.
C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
The invention relates generally to optical agents, including phototherapeutic agents, for biomedical applications, including phototherapy. The invention includes optical agents, and related therapeutic methods, comprising alicyclic diaza compounds, including 1,2 diaza heterocyclic compounds, having a photolabile N—N bond directly or indirectly linked to at least one carbocyclic aromatic and/or heterocyclic aromatic group. In some embodiments, for example, the invention provides alicyclic diaza compounds for phototherapeutic methods having a photolabile N—N bond that undergoes photoactivated cleavage to produce reactive species, such as radicals, ions, etc., that achieve a desired therapeutic effect, such as selective and/or localized tissue damage and/or cell death.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
The present invention provides processes for the demethylation of an N-methyl morphinan comprising a ketone functional group. In particular, the invention provides methods for the protection of the ketone functional group such that impurities are not generated during the demethylation of the N-methyl morphinan.
A process for purifying Mo-99 from an acidic solution obtained by dissolving an irradiated solid target comprising uranium in an acidic medium, or from an acidic solution comprising uranium and which has previously been irradiated in a nuclear reactor, or from an acidic solution comprising uranium and which has been used as reactor fuel in a homogeneous reactor, the process comprising contacting the acidic solution with an adsorbent comprising a zirconium oxide, zirconium hydroxide, zirconium alkoxide, zirconium halide and/or zirconium oxide halide, and eluting the Mo-99 from the adsorbent using a solution of a strong base, the eluate then being subjected to a subsequent purification process involving an alkaline-based Mo-99 chromatographic recovery step on an anion exchange material. Also provided is apparatus for carrying out the process.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
The present invention provides processes for the preparation of N-alkyl morphinans without the isolation of nor-morphinan intermediates. In particular, the invention provides tandem hydrolysis/alkylation reactions for the synthesis of N-alkyl morphinans.
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
80.
(+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF
The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
C07D 217/20 - Radicaux aralkyle avec des atomes d'oxygène liés directement au noyau aromatique dudit radical aralkyle, p. ex. papavérine
C07D 489/00 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
C07D 489/10 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne condensés avec des carbocycles ou avec des systèmes carbocycliques avec un pont entre les positions 6 et 14
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A slurry dispensing system (10) is disclosed. A peristaltic pump (28) may direct a flow of slurry out of a horizontal mixer (20) to a slurry dispenser (140). This slurry dispenser (140) may be operated on a programmed manner by a controller (260) to dispense slurry into a container (36). Both a bypass valve (172) and a dispensing valve (204) of the slurry dispenser may be opened/closed on a programmed basis by the controller (260) to deliver slurry to a container (36), such as a glass column. Slurry may be intermittently directed into a metering chamber (194) of the slurry dispenser (140), while the remainder of the slurry being directed into the slurry dispenser (140) may be recirculated back to the horizontal mixer (20).
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07D 217/20 - Radicaux aralkyle avec des atomes d'oxygène liés directement au noyau aromatique dudit radical aralkyle, p. ex. papavérine
A horizontal mixer (50) is disclosed. Multiple blades (92) are affixed to and rotate with a tumbler (80) of the mixer (50). These blades (92) extend within an interior mixing chamber (90) and are center-angled so as to promote a desirable mixing action within this chamber (90) (e.g. so as to fold a slurry within the chamber (90) onto itself). One characterization is that the blades (92) are oriented so as to direct a flow toward a common outlet region (78) within the tumbler (80) throughout at least a certain rotational angle. The mixer (50) is particularly suited for realizing a desirable homogeneity of particles within a slurry from which radioisotopes may be produced.
Described herein are optical agents, including compositions, preparations and formulations, for monitoring the pH of a fluid. Optical agents described herein include photonic nanostructures and nanoassemblies including supramolecular structures, such as shell cross-linked micelles, that incorporate at least one linking group comprising one or more photoactive moieties that provide functionality as exogenous agents for a range of pH monitoring applications. Optical agents described herein comprise supramolecular structures having linking groups imparting useful optical and structural functionality. In an embodiment, for example, the presence of linking groups function to covalently cross link polymer components to provide a cross-linked shell stabilized supramolecular structure, and also impart useful optical functionality, for example by functioning as a fluorophore.
G01N 33/84 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des composés inorganiques ou le pH
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
C08F 8/00 - Modification chimique par post-traitement
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
85.
FUNCTIONAL, CROSS-LINKED NANOSTRUCTURES FOR TANDEM OPTICAL IMAGING AND THERAPY
The present invention provides optical agents comprising optically functional cross linked supramolecular structures and assemblies useful for tandem optical imaging and therapy. Supramolecular structures and assemblies of the present invention include optically functional shell-cross linked micelles wherein optical functionality is achieved via incorporation of one or more linking groups that include one or more photoactive moieties. The present invention further includes imaging and therapeutic methods using one or more optical agents of the present invention including optically functional shell cross-linked micelles having an associated therapeutic agent.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
The present invention provides processes for the preparation of saturated ketone morphinan compounds from a morphinan comprising an allyl alcohol ring moiety, wherein the final product has a low metal content. In particular, the invention provides processes that utilize isomerization reactions catalyzed by transition metal catalysts and the subsequent removal of the transition metal using metal scavengers.
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
A syringe product (40) comprises a syringe barrel (42) having a fluid- containment wall (48) made using a polymer composition comprising a metallocene polypropylene polymer and an organophosphate clarifier. The syringe product may be prefilled with an injectable medical formulation (62) prior to use. The syringe product may be used to administer an injectable medical formulation to a patient.
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The invention relates generally to optical agents for biomedical applications, including phototherapy. Azide derivatives of some embodiments have an azido group that is directly attached to a phenyl ring having a combination of electron donating groups and electron withdrawing groups. Optical agents of the invention include phototherapeutic agents, including Type 1 phototherapeutic agents that enable a versatile phototherapy platform for treatment of a range of pathological conditions, including the treatment of cancers, stensosis and inflammation. The invention further provides preparations and formulations comprising azide derivatives and related methods of making and using azide optical agents in in vivo or ex vivo biomedical procedures.
C07C 247/16 - Composés contenant des groupes azido avec des groupes azido liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné
C07C 247/18 - Composés contenant des groupes azido avec des groupes azido liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné étant substitué de plus par des groupes carboxyle
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61K 31/655 - Composés azoïques(-N=N-), diazoïques (=N2), azoxy (N-O-N ou N(=O)-N), azido (-N3) ou diazoamino (-N=N-N)
A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
C07D 217/20 - Radicaux aralkyle avec des atomes d'oxygène liés directement au noyau aromatique dudit radical aralkyle, p. ex. papavérine
A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
C07D 489/00 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
C07D 489/10 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne condensés avec des carbocycles ou avec des systèmes carbocycliques avec un pont entre les positions 6 et 14
The invention relates generally to optical agents for biomedical applications, including phototherapy. Provided are sulfenamide compounds having an acyclic S-N bond with at least one aromatic and/or heterocyclic aromatic group providing phototherapeutic agents, including Type 1 phototherapeutic agents. Optical agents of the invention enable a versatile phototherapy platform for treatment of a range of pathological conditions, including the treatment of cancers, stensosis and inflammation. The invention further provides preparations and formulations comprising the sulfenamide optical agents and related methods of making and using sulfenamide optical agents in an in vivo or ex vivo biomedical procedure.
C07D 223/24 - Dibenz [b, f] azépinesDibenz [b, f] azépines hydrogénées avec des radicaux hydrocarbonés, substitués par des atomes d'azote, liés à l'atome d'azote du cycle
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
C07C 313/24 - Sulfénamides ayant des atomes de soufre de groupes sulfénamide liés à des atomes de carbone de cycles aromatiques à six chaînons
A syringe plunger drive assembly (132) for advancing a syringe plunger (90a/b) in at least one direction (e.g., to deliver fluid). In one embodiment, this syringe plunger drive assembly (132) may be constructed of all non-ferrous components and includes a piezoelectric pump (110) that supplies pressurized hydraulic fluid to a syringe plunger driver (134). The syringe plunger driver (134) may be in the form of a single acting hydraulic cylinder including a piston rod (140) movable in first and second generally opposing directions (e.g. forward and rearward). A valve (152) and a reservoir (154) may be fluidly interconnected between the piezoelectric pump (110) and the syringe plunger driver (134) to facilitate the pumping of hydraulic fluid to the syringe plunger driver (134).
The present disclosure is directed to a process for preparing an alkylated triiodo-substituted arylamide, such as iodixanol, the process comprising contacting a triiodo-substituted arylamide, such as 5-acetamido-N,N'-bis(2,3-dihydroxylpropyl)-2,4,6-triiodoisophthalamide, and an alkylating agent in the presence of a base and a mixed solvent system comprising a non-aqueous solvent and water, wherein the volume ratio of the non-aqueous solvent to water is greater than 1:1. The process advantageously enables the concentration of any impurities or undesirable byproduct from the reaction to be reduced, while increasing the yield of the desired reaction product.
C07C 231/08 - Préparation d'amides d'acides carboxyliques à partir d'amides par réaction sur les atomes d'azote de groupes carboxamide
C07C 231/12 - Préparation d'amides d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes carboxamide
C07C 237/32 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons non condensé du squelette carboné ayant l'atome d'azote du groupe carboxamide lié à un atome de carbone acyclique d'un radical hydrocarboné substitué par des atomes d'oxygène
94.
SYSTEMS AND METHOD FOR ASSESSING FUNCTIONALITY OF DUAL CHECK VALVE ARRANGEMENTS IN MEDICAL TUBING SETS
A dual one-way check valve arrangement (300) that may be used for assessing an operating condition of at least one of first and second check valves (304, 308) situated in series along/within a section of a patient-specific section of tubing (244). A pressure sensor (332) may be associated with at least part of the flow path between the first and second check valves (304, 308) and may be operable to provide an indication of a failed condition of at least one of the first and second check valves (304, 308). In one embodiment, the pressure sensor (332) may change from a first state to a second state upon fluid pressure within the flow path between the first and second check valves (304, 308) falling below a predetermined level. For instance, the predetermined level may be a cracking pressure of at least one of the first and second check valves (304, 308). The change in state may be visually discernible on an exterior of the pressure sensor (332).
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
95.
REDUCTION OF FUSED BICYCLIC IMPURITIES IN TRIIODINATED X-RAY CONTRAST MEDIA
The present disclosure generally relates to an improved process for alkylating a triiodo-substituted arylamide to form a compound suitable for use as an X-ray contrast agent. More particularly, the present disclosure is directed to such a process that limits the formation of fused bicyclic impurities, such as Impurity G, in the alkylation reaction mixture.
C07C 231/12 - Préparation d'amides d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes carboxamide
C07C 235/16 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone acycliques et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné le squelette carboné étant acyclique et saturé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
C07C 237/32 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons non condensé du squelette carboné ayant l'atome d'azote du groupe carboxamide lié à un atome de carbone acyclique d'un radical hydrocarboné substitué par des atomes d'oxygène
96.
METHODS FOR PRODUCING HYDROCODONE, HYDROMORPHONE OR A DERIVATIVE THEREOF
The present disclosure generally relates to methods for producing opioid derivatives. More particularly, the present disclosure relates to the preparation of hydromorphone, hydrocodone, or a derivative thereof, by means of a non-catalytic hydrogenation reaction of thebaine, oripavine or a derivative thereof, respectively, using a hydrazide reagent, followed by hydrolysis of the hydrogenated intermediate at a low temperature and for a short period of time. Additionally, the present disclosure relates to a composition comprising the desired hydromorphone, hydrocodone, or a derivative thereof, in combination with a 6-beta compound that is structurally related thereto.
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
The present invention provides an efficient process for the preparation of hexahydroisoquinolines from amides. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.
The present invention provides an efficient process for the preparation of hexahydroisoquinolines from dihydroisoquinolines. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.
The present invention provides processes for the preparation of 10-keto and/or 10-hydroxy morphinans. In particular, the invention provides to processes for preparing a 10-keto morphinan by chromium-catalyzed benzylic oxidation of a morphinan with a periodic acid.
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
This invention is directed to non-benzenoid aromatic compounds. Other aspects include methods of using non-benzenoid aromatic compounds for imaging and phototherapeutic uses thereof. Non-benzenoid compounds provided herein generally have one or more substituent groups which allow tailoring of the spectral properties or provide photoreactivity or targeting ability.
